Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
oleh: Olaf Penack, Olaf Penack, Christophe Peczynski, Christophe Peczynski, Christophe Peczynski, Christian Koenecke, Christian Koenecke, Emmanuelle Polge, Emmanuelle Polge, Emmanuelle Polge, Robin Sanderson, Ibrahim Yakoub-Agha, Nathalie Fegueux, Michael Daskalakis, Michael Daskalakis, Matthew Collin, Peter Dreger, Nicolaus Kröger, Urs Schanz, Adrian Bloor, Arnold Ganser, Caroline Besley, Caroline Besley, Gerald G. Wulf, Urban Novak, Ivan Moiseev, Ivan Moiseev, Hélène Schoemans, Hélène Schoemans, Grzegorz W. Basak, Grzegorz W. Basak, Christian Chabannon, Christian Chabannon, Anna Sureda, Anna Sureda, Bertram Glass, Bertram Glass, Zinaida Peric, Zinaida Peric
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2023-09-01 |
Deskripsi
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.